Genetic Testing For Color Vision Makes Commercial Debut for Military Applications
By Dan Buckland,
medGadget
| 06. 12. 2012
Possibly heralding a new era in the use of genetic testing for hiring decisions,
Genevolve (Albuquerque, NM) announced at the recent Aerospace Medicine Association conference in Atlanta, GA a new “military grade” test for inherited color blindness. A few years ago we
posted on research done at the Neitz lab at the University of Washington that used gene therapy to cure color blindness in monkeys. Aspects of that research were used to produce the technology Genevolve uses for its test, called Eyedox. Eyedox uses a buccal swab that is sent to the company, which analyzes the sample for color genes (likely the ones detailed in this review
paper by Neitz) and returns the type of deficiency and severity on a scale of 1-100, 100 being normal.
A press release from the company details what they envision the test could be used for:
“This prevents a qualified applicant from being denied entry into a field they can adequately perform and eliminates cheating or administrator bias that may allow some severely colorblinds to slip through the system,” says [President of Genevolve]...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...